Sarepta Therapeutics has appointed Dr. Michael Severino as its new CEO, effective July 28, 2026, succeeding Doug Ingram, who is retiring but will support the transition until the end of 2026. Dr. Severino brings over 25 years of biopharmaceutical experience, having previously served as CEO of Tessera Therapeutics and in leadership roles at AbbVie. He is expected to lead Sarepta in advancing its precision genetic medicine initiatives, particularly in the Duchenne muscular dystrophy space, where the company has made significant strides. The Board expressed gratitude for Ingram’s leadership in transforming Sarepta into a leader in genetic medicine.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.businesswire.com/news/home/20260727284554/en/Sarepta-Therapeutics-Appoints-Michael-Severino-M.D.-Chief-Executive-Officer
